ReviewCurrent oncology (Toronto, Ont.)2022
Not All Canadian Cancer Patients Are Equal-Disparities in Public Cancer Drug Funding across Canada.
Review in Current oncology (Toronto, Ont.), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Interventions to improve access to cancer care in underserved populations in high income countries: a systematic review.Oncology reviews · 2024Pooled it
- From MAiD Referral to Targeted Therapy Success: A Case ofReports (MDPI) · 2025Article
- Cancer Care Experiences Among Adolescents, Caregivers, and Health Care Providers in a Regional Canadian Context: Protocol for a Qualitative Study.JMIR research protocols · 2025Article
- Trends in the Cost and Utilization of Publicly Reimbursed Cancer Medications Dispensed as Take-Home Treatments from 2017-2021.Current oncology (Toronto, Ont.) · 2025Article
- Insights from GoFundMe posts: Analyzing GoFundMe financial aid requests from brain tumor patients in Ontario, Canada.Neuro-oncology practice · 2025Article
- Consequences of Canada's Drug Agency Reimbursement Recommendations for New Medicines and Pan-Canadian Pharmaceutical Alliance Price Negotiations on Patient Access.ClinicoEconomics and outcomes research : CEOR · 2025Article
- Article
- New Anticancer Drugs: Reliably Assessing "Value" While Addressing High Prices.Current oncology (Toronto, Ont.) · 2024Article
- Access to Oncology Medicines in Canada: Consensus Forum for Recommendations for Improvement.Current oncology (Toronto, Ont.) · 2024Article
- Impact of Systemic Delays for Patient Access to Oncology Drugs on Clinical, Economic, and Quality of Life Outcomes in Canada: A Call to Action.Current oncology (Toronto, Ont.) · 2024Review
- Tackling financial toxicity related to cancer care in Canada.CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne · 2024Article
- Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada.Current oncology (Toronto, Ont.) · 2024Article
- Timeliness of Health Technology Assessments and Price Negotiations for Oncology Drugs in Canada.ClinicoEconomics and outcomes research : CEOR · 2024Article
- Current Challenges and Disparities in the Delivery of Equitable Breast Cancer Care in Canada.Current oncology (Toronto, Ont.) · 2023Review
- Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience.Current oncology (Toronto, Ont.) · 2023Article
- Canadian Consensus Recommendations on the Management of KRAS G12C-Mutated NSCLC.Current oncology (Toronto, Ont.) · 2023Article
- Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2022Article
- Access to Cancer Drugs in Canada.Current oncology (Toronto, Ont.) · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Canada lacks a national drug insurance plan. The home province or territory of a patient determines which cancer drugs are available on the public formulary, who is eligible for public coverage and what portion of the financial burden of cancer care falls to the individual. This narrative review describes the current interprovincial disparities in access to cancer drugs across Canada. Health technology assessment (HTA) of drugs at a provincial and territory level is a closed process, does not necessarily follow the recommendations of national HTA and leads to further delays in drug access. The public coverage of take-home cancer drugs (THCDs) in Ontario and the Atlantic provinces is often fragmented, unnecessarily complex and a barrier to cancer drug access. Policy solutions to address inter-provincial formulary variation and poor access to THCDs are discussed.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.